Huo Zhiming, Sinha Ruchi, McNeela Edel A, Borrow Ray, Giemza Rafaela, Cosgrove Catherine, Heath Paul T, Mills Kingston H G, Rappuoli Rino, Griffin George E, Lewis David J M
St. George's Vaccine Institute, London, United Kingdom.
Infect Immun. 2005 Dec;73(12):8256-65. doi: 10.1128/IAI.73.12.8256-8265.2005.
Thirty-six healthy volunteers received either a single intramuscular injection of Neisseria meningitidis serogroup C polysaccharide (MCP)-CRM197 conjugate vaccine in alum or two nasal insufflations 28 days apart of the same vaccine powder, without alum, mixed with chitosan. Nasal immunization was well tolerated, with fewer symptoms reported than after intramuscular injection. The geometric mean concentrations of MCP-specific immunoglobulin G (IgG) after one nasal immunization were 3.25 microg/ml in naïve subjects and 14.4 microg/ml in subjects previously immunized parenterally, compared with 4.30 microg/ml in naïve subjects immunized intramuscularly. The geometric mean titer of serum bactericidal antibody (SBA) rose 24-fold after two nasal immunizations in naïve subjects and was comparable to parenteral immunization (1,080 versus 1,625). All subjects achieved SBA titers associated with protection after two nasal immunizations: even those with titers of <8 at entry. A single nasal immunization boosted the SBA titer to > or =128 in 96% of previously immunized subjects, and two immunizations achieved this level in 92% of naive subjects. MCP-specific IgG levels were approximately 70% IgG2 and approximately 20% IgG1 after nasal or intramuscular immunization. Increases in CRM197-specific IgG and diphtheria toxin-neutralizing activity were observed after nasal or intramuscular immunization, with balanced IgG1/IgG2 and higher IgG4. Significant MCP-specific secretory IgA was detected in nasal wash only after nasal immunization and predominantly on the immunized side. Simple nasal insufflation of existing MCP-CRM197 conjugate vaccines in chitosan offers an inexpensive but effective needle-free prime and boost against serogroup C N. meningitidis and diphtheria.
36名健康志愿者分别接受了以下两种免疫方式:一种是在明矾佐剂中进行单次肌内注射C群脑膜炎奈瑟菌多糖(MCP)-CRM197结合疫苗;另一种是在不使用明矾的情况下,将相同的疫苗粉末与壳聚糖混合,分28天进行两次鼻内给药。鼻内免疫耐受性良好,报告的症状比肌内注射后更少。初次免疫的受试者在一次鼻内免疫后,MCP特异性免疫球蛋白G(IgG)的几何平均浓度为3.25微克/毫升,之前接受过肠道外免疫的受试者为14.4微克/毫升,而肌内免疫的初次免疫受试者为4.30微克/毫升。在初次免疫的受试者中,两次鼻内免疫后血清杀菌抗体(SBA)的几何平均滴度升高了24倍,与肠道外免疫相当(分别为1080和1625)。所有受试者在两次鼻内免疫后均达到了与保护相关的SBA滴度:即使是那些初始滴度<8的受试者。单次鼻内免疫使96%之前免疫过的受试者的SBA滴度提高到≥128,两次免疫使92%的初次免疫受试者达到了这一水平。鼻内或肌内免疫后,MCP特异性IgG水平约70%为IgG2,约20%为IgG1。鼻内或肌内免疫后观察到CRM197特异性IgG和白喉毒素中和活性增加,IgG1/IgG2平衡且IgG4更高。仅在鼻内免疫后,在鼻洗液中检测到显著的MCP特异性分泌型IgA,且主要在免疫侧。将现有的MCP-CRM197结合疫苗简单地与壳聚糖进行鼻内给药,提供了一种廉价但有效的无针初免和加强免疫方法,可预防C群脑膜炎奈瑟菌和白喉。